Healthcare Industry News:  Listeria 

Diagnostics Personnel

 News Release - February 20, 2008

Strategic Diagnostics Expands Executive Team with 26-Year Veteran from Agilent Technologies

Fran DiNuzzo Joins SDI as Executive VP and Chief Commercial Officer

NEWARK, Del.--(HSMN NewsFeed)--Strategic Diagnostics Inc. (Nasdaq:SDIX ) - announced today that Francis (Fran) M. DiNuzzo has been named Executive Vice President and Chief Commercial Officer, effective February 25. Mr. DiNuzzo was most recently an executive in the BioAnalytical business unit of Agilent Technologies Inc.

Mr. DiNuzzo has more than 26 years of business leadership experience in life and analytical science markets. During his tenure at Agilent, Mr. DiNuzzo held key leadership positions within the Company’s BioAnalytical business, including serving as Vice President and General Manager of the Chemical Solutions Business Unit; the Consumables and Services Business; and the Integrated Biology Solutions Business. In each of these roles, he led the development and execution of “Market Focused” strategies and the implementation of programs to create sustained profitable growth. Most recently as a business development executive, he held a lead role in the Stratagene and Velocity 11 acquisitions.

“Strategic Diagnostics is accelerating its emergence as a leading antibody technology company and we are excited to add Fran DiNuzzo, a proven industry leader, to our talented team,” commented Matthew H. Knight, the Company’s President and Chief Executive Officer. “Our new Genomic Antibody Technology™ is rapidly becoming recognized as a breakthrough in the production of critical reagents for proteomic research. In addition, large pharmaceutical, biotechnology and academic customers are increasingly utilizing SDI products, services and technology in a wide range of drug and biomarker research and discovery. The progress we have made to date has been substantial, and adding a proven executive and business development professional like Fran to our team will enable us to take our antibody business to the next level.”

“I am excited to be joining the Strategic Diagnostics team,” added Mr. DiNuzzo. “I believe the company has tremendous opportunities for growth in the rapidly growing life science research and diagnostics markets and continuing opportunities to expand the value created for customers in foods, environmental and associated testing markets. I look forward to working with Matt and the executive team to continue building the business, expanding our customer base and delivering profitable growth for our shareholders.”

About Strategic Diagnostics Inc.

Strategic Diagnostics Inc. (SDI) is an antibody technology company; developing, commercializing and marketing innovative and proprietary biotechnology solutions that preserve and enhance the quality of human health. SDI’s antibody division supplies critical reagents used in the diagnosis of disease. The Company’s new Genomic Antibody Technology™ is gaining wide adoption in proteomic research, and drug/biomarker discovery among academic, biotech and large pharmaceutical customers. SDI’s industrial immunoassays represent state of the art technology for rapid, cost effective detection of food and water contaminants. The Company’s RapidChek® kits are the fastest growing method for the detection of pathogens like E coli, Salmonella and Listeria in the processing and manufacturing of food and beverages. SDI technology is also finding new applications in strategic emerging markets such as renewable fuel where the application of its patent pending phage technology is being developed to increase corn to ethanol profits through higher yields at a lower cost. For more information, visit the Company’s website at

This news release contains forward-looking statements reflecting SDI's current expectations. When used in this press release, the words “anticipate”, “could”, “enable”, “estimate”, “intend”, “expect”, “believe”, “potential”, “will”, “should”, “project”, “plan” and similar expressions as they relate to SDI are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDI at this time. Such risks and uncertainties include, without limitation, changes in demand for products, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party, including AOAC, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDI's public filings with the U.S. Securities and Exchange Commission.

Source: Strategic Diagnostics

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.